Teleflex Receives 2018 Medical Design Excellence Award (MDEA) for Arrow® AC3 OptimusTM Intra-Aortic Balloon Pump
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, is proud to announce the Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the bronze winner in the cardiovascular device category of the 20th annual Medical Design Excellence Awards competition. The 2018 winning products were announced at the MDEA ceremony held at the Jacob K. Javits Convention Center in New York.
The AC3 Optimus IABP helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy. Clinicians may use the pump on patients with the most arrhythmias or with heart rates as high as 200 beats per minute.1, 2 In IABP therapy, a physician inserts an intra-aortic balloon catheter into an artery, and using x-ray or imaging, advances the catheter into the aorta. An IABP console, connected to the catheter, controls the inflation and deflation of the balloon.
“We are proud to receive this honor. As innovators in intra-aortic balloon pumping technology, we have made it our commitment to provide a solution that advances the performance and reliability of automated therapy," said Stew Strong, President and General Manager of the Interventional Division at Teleflex. "This award is a testament to our passion and dedication to providing purpose-driven innovation to improve the health and quality of people’s lives.”
The MDEA competition is the medical technology industry’s premier design competition, committed to searching for the world’s highest caliber medical devices, products, systems or packaging available on the market. Products were judged based on design and engineering innovation, function and user-related innovation, patient benefits, business benefits, and overall benefit to the healthcare system.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com
Teleflex is the home of Arrow® Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose. ®
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, AC3 Optimus, Deknatel, Hudson
RCI, LMA, UroLift, Pilling, Rusch and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
©2018 Teleflex Incorporated. All rights reserved. MC-004336
- Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic balloon pump timing using an intra beat dicrotic notch prediction algorithm. Ann Thorac Surg. 2005;79(3):1017-1022. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor. Co-authors J. Bovelander, R. Hanania, and P. Hanlon are current or former employees of the study sponsor.
- Donelli A, Jansen JRC, Hoeksel B, et. al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhytmic human aortic pressure signals. J Clin Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor. Co-authors J. Bovelander and R. Hanania are current or former employees of the study sponsor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181029005039/en/